CH Biotech R&D Co., Ltd. (TPE:6534)

CH Biotech R&D Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	626.66	478.86	939.93	530.02	321.01	324.01
Short-Term Investments	2.93	3.28	3.07	3.07	5.78	5.86
Cash & Short-Term Investments	629.59	482.13	943	533.1	326.79	329.87
Cash Growth	-23.35%	-48.87%	76.89%	63.13%	-0.93%	15.75%
Accounts Receivable	304.75	162.83	106.07	33.3	161.14	36.44
Other Receivables	54.43	56.62	44.8	42.97	29.13	20.2
Receivables	359.18	219.45	150.87	76.27	190.27	56.64
Inventory	82.37	122.1	119.21	177.26	125.01	42.49
Prepaid Expenses	24.58	26.5	18.59	12.99	10.74	7.86
Other Current Assets	2.28	2.4	3.76	4.07	1.71	5.14
Total Current Assets	1,098	852.59	1,235	803.69	654.53	442
Property, Plant & Equipment	2,651	2,718	2,361	2,365	2,349	2,380
Long-Term Investments	27.88	29.1	29.36	-	-	-
Goodwill	2.45	2.45	2.45	2.45	2.45	2.45
Other Intangible Assets	6.55	3.43	3.71	5.82	5.39	8.35
Long-Term Deferred Tax Assets	12.71	2.84	3.21	2	2.23	3.54
Other Long-Term Assets	28.6	20.7	14.37	16.08	15.24	42.59
Total Assets	3,827	3,629	3,649	3,195	3,029	2,879
Accounts Payable	7.59	8.84	9.26	9.62	20.71	6.77
Accrued Expenses	0.13	0.23	0.35	0.41	0.19	4.45
Short-Term Debt	495	290	190	120	188	243
Current Portion of Long-Term Debt	127.28	107.28	385.6	120	140.76	94.18
Current Portion of Leases	25.16	24.33	28.18	21.62	16.83	15.23
Current Income Taxes Payable	119.06	54.11	119.28	76.02	68.35	28.75
Current Unearned Revenue	0.29	0.32	0.47	0.3	0.35	0.5
Other Current Liabilities	124.6	161.82	149.19	119.56	93.66	56.68
Total Current Liabilities	899.11	646.93	882.32	467.52	528.84	449.56
Long-Term Debt	105.62	189.26	-	385.6	523.18	680.62
Long-Term Leases	135.6	136.46	241.38	247.66	253.51	269.21
Long-Term Deferred Tax Liabilities	-	2.38	-	2.56	-	-
Other Long-Term Liabilities	0.48	0.21	-	-	-	-
Total Liabilities	1,148	982.44	1,129	1,108	1,306	1,399
Common Stock	1,028	1,028	1,028	970.83	844.2	844.2
Additional Paid-In Capital	718.33	718.26	717.64	331.32	331.32	331.32
Retained Earnings	944.25	877.19	771.2	782.37	570.21	320.92
Comprehensive Income & Other	-12.59	22.42	3.3	3.16	-22.52	-16.55
Total Common Equity	2,678	2,646	2,520	2,088	1,723	1,480
Minority Interest	0.72	0.87	-	-	-	-
Shareholders' Equity	2,679	2,647	2,520	2,088	1,723	1,480
Total Liabilities & Equity	3,827	3,629	3,649	3,195	3,029	2,879
Total Debt	888.66	747.33	845.16	894.89	1,122	1,302
Net Cash (Debt)	-259.08	-265.19	97.84	-361.79	-795.48	-972.37
Net Cash Per Share	-2.51	-2.57	1.00	-3.67	-8.11	-9.96
Filing Date Shares Outstanding	102.8	102.8	102.8	97.08	97.08	97.08
Total Common Shares Outstanding	102.8	102.8	102.8	97.08	97.08	97.08
Working Capital	198.89	205.66	353.1	336.16	125.69	-7.55
Book Value Per Share	26.05	25.74	24.52	21.50	17.75	15.24
Tangible Book Value	2,669	2,640	2,514	2,079	1,715	1,469
Tangible Book Value Per Share	25.96	25.68	24.46	21.42	17.67	15.13
Land	496.26	546.51	143.24	143.26	109.81	112.11
Buildings	1,993	1,949	1,905	1,864	1,448	1,340
Machinery	841.81	823.54	576.15	476.33	358.65	325.23
Construction In Progress	34.67	40.12	60.5	73.28	508.86	592.42

Source: S&P Global Market Intelligence. Standard template. Financial Sources.